搜索
Shattuck Labs Inc
STTK添加自选
7.050USD
+0.540+8.29%
收盘 07/02, 13:00（美东）报价延迟15分钟
532.85M总市值
亏损市盈率 TTM
关于 Shattuck Labs Inc 公司
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Shattuck Labs Inc简介
公司代码STTK
公司名称Shattuck Labs Inc
上市日期Oct 09, 2020
CEOSchreiber (Taylor)
员工数量44
证券类型Ordinary Share
年结日Oct 09
公司地址500 W. 5Th Street
城市AUSTIN
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编78701
电话15129004690
网址https://www.shattucklabs.com/
公司代码STTK
上市日期Oct 09, 2020
CEOSchreiber (Taylor)
Shattuck Labs Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
122.22K
+20.95%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
93.37K
+12.68%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Dr. Arundathy Nirmalini (Lini) Pandite
Dr. Arundathy Nirmalini (Lini) Pandite
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
--
--
Mr. Andrew R. Neill
Mr. Andrew R. Neill
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Mr. Conor Richardson, CPA
Mr. Conor Richardson, CPA
Senior Director, Finance & Investor Relations
Senior Director, Finance & Investor Relations
--
--
Dr. Abhinav A. Shukla, Ph.D.
Dr. Abhinav A. Shukla, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
122.22K
+20.95%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
93.37K
+12.68%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Dr. Arundathy Nirmalini (Lini) Pandite
Dr. Arundathy Nirmalini (Lini) Pandite
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
--
--
常见问题
Shattuck Labs Inc的前五大股东是谁？
Shattuck Labs Inc 的前五大股东如下：Dr. Taylor Schreiber, M.D., Ph.D.
有多少机构持有Shattuck Labs Inc(STTK)的股份？
截至2026Q1，共有189家机构持有Shattuck Labs Inc的股份，合计持有的股份价值约为50.41M，占公司总股份的65.78%。与2025Q4相比，机构持股有所增加，增幅为9741871.00。